CN113262259A - Chinese medicinal composition for treating infertility and preparation method thereof - Google Patents
Chinese medicinal composition for treating infertility and preparation method thereof Download PDFInfo
- Publication number
- CN113262259A CN113262259A CN202110734255.0A CN202110734255A CN113262259A CN 113262259 A CN113262259 A CN 113262259A CN 202110734255 A CN202110734255 A CN 202110734255A CN 113262259 A CN113262259 A CN 113262259A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- weight
- treatment
- infertility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 208000000509 infertility Diseases 0.000 title claims abstract description 48
- 230000036512 infertility Effects 0.000 title claims abstract description 48
- 231100000535 infertility Toxicity 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 41
- 239000006041 probiotic Substances 0.000 claims abstract description 30
- 235000018291 probiotics Nutrition 0.000 claims abstract description 30
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 244000178320 Vaccaria pyramidata Species 0.000 claims abstract description 12
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims abstract description 11
- 244000078912 Trichosanthes cucumerina Species 0.000 claims abstract description 11
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims abstract description 11
- 244000018716 Impatiens biflora Species 0.000 claims abstract description 10
- 235000015912 Impatiens biflora Nutrition 0.000 claims abstract description 10
- 235000005155 Tanacetum balsamita Nutrition 0.000 claims abstract description 10
- 235000015655 Crocus sativus Nutrition 0.000 claims abstract description 9
- 244000124209 Crocus sativus Species 0.000 claims abstract description 9
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 9
- 241000722953 Akebia Species 0.000 claims abstract description 8
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 8
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 8
- 241001673966 Magnolia officinalis Species 0.000 claims abstract description 8
- 244000011358 Patrinia scabiosaefolia Species 0.000 claims abstract description 8
- 235000009267 Patrinia scabiosaefolia Nutrition 0.000 claims abstract description 8
- 241000270666 Testudines Species 0.000 claims abstract description 8
- 241000427159 Achyranthes Species 0.000 claims abstract description 6
- 241000893536 Epimedium Species 0.000 claims abstract description 6
- 235000018905 epimedium Nutrition 0.000 claims abstract description 6
- 241000208682 Liquidambar Species 0.000 claims abstract description 3
- 235000006552 Liquidambar styraciflua Nutrition 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 78
- 238000000855 fermentation Methods 0.000 claims description 54
- 230000004151 fermentation Effects 0.000 claims description 46
- 239000000284 extract Substances 0.000 claims description 29
- 230000000529 probiotic effect Effects 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 18
- 241000186660 Lactobacillus Species 0.000 claims description 17
- 239000001888 Peptone Substances 0.000 claims description 17
- 108010080698 Peptones Proteins 0.000 claims description 17
- 235000015278 beef Nutrition 0.000 claims description 17
- 229940041514 candida albicans extract Drugs 0.000 claims description 17
- 229940039696 lactobacillus Drugs 0.000 claims description 17
- 235000019319 peptone Nutrition 0.000 claims description 17
- 239000012138 yeast extract Substances 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
- 230000001580 bacterial effect Effects 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 16
- 239000008103 glucose Substances 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 16
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 16
- 239000011654 magnesium acetate Substances 0.000 claims description 16
- 229940069446 magnesium acetate Drugs 0.000 claims description 16
- 235000011285 magnesium acetate Nutrition 0.000 claims description 16
- 238000011218 seed culture Methods 0.000 claims description 16
- 239000010802 sludge Substances 0.000 claims description 16
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims description 16
- 238000004108 freeze drying Methods 0.000 claims description 14
- 235000015097 nutrients Nutrition 0.000 claims description 14
- 244000057717 Streptococcus lactis Species 0.000 claims description 10
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 10
- 229940071125 manganese acetate Drugs 0.000 claims description 10
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 claims description 10
- 238000000108 ultra-filtration Methods 0.000 claims description 10
- 235000007650 Aralia spinosa Nutrition 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 9
- 241000949456 Zanthoxylum Species 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 235000010724 Wisteria floribunda Nutrition 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 8
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 8
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 7
- 238000004880 explosion Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 229920002492 poly(sulfone) Polymers 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 240000007890 Leonurus cardiaca Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 50
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 abstract description 2
- 240000008384 Capsicum annuum var. annuum Species 0.000 abstract description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 32
- 230000001737 promoting effect Effects 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 208000004880 Polyuria Diseases 0.000 description 15
- 230000035619 diuresis Effects 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 230000035935 pregnancy Effects 0.000 description 12
- 230000005906 menstruation Effects 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 230000016087 ovulation Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 239000003163 gonadal steroid hormone Substances 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 201000000736 Amenorrhea Diseases 0.000 description 7
- 206010001928 Amenorrhoea Diseases 0.000 description 7
- 241000207925 Leonurus Species 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 231100000540 amenorrhea Toxicity 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 6
- 108010053775 Nisin Proteins 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 210000004696 endometrium Anatomy 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000004309 nisin Substances 0.000 description 6
- 235000010297 nisin Nutrition 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 6
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000002435 tendon Anatomy 0.000 description 6
- 206010036049 Polycystic ovaries Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 206010002659 Anovulatory cycle Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 238000000889 atomisation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 238000009461 vacuum packaging Methods 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 description 3
- 206010030302 Oliguria Diseases 0.000 description 3
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010304 firing Methods 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 208000024765 knee pain Diseases 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 229940040129 luteinizing hormone Drugs 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 230000024121 nodulation Effects 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 240000000031 Achyranthes bidentata Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241001362421 Epimedium brevicornu Species 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 235000015512 Liquidambar formosana Nutrition 0.000 description 2
- 241000893545 Liquidambar formosana Species 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 1
- 244000036770 Akebia trifoliata Species 0.000 description 1
- 235000012980 Akebia trifoliata Nutrition 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000219321 Caryophyllaceae Species 0.000 description 1
- 241000336291 Cistanche deserticola Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 240000003421 Dianthus chinensis Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 241000142952 Hamamelidaceae Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000831743 Lactobacillus parafarraginis Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000371451 Lactococcus fujiensis Species 0.000 description 1
- 241001084594 Leptostachya Species 0.000 description 1
- 241000514719 Mactra quadrangularis Species 0.000 description 1
- FYYHWMGAXLPEAU-RNFDNDRNSA-N Magnesium-28 Chemical group [28Mg] FYYHWMGAXLPEAU-RNFDNDRNSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 208000011707 Ovulation disease Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000736919 Pelodiscus sinensis Species 0.000 description 1
- 241001503951 Phoma Species 0.000 description 1
- 241001023442 Populus suaveolens Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 240000006023 Trichosanthes kirilowii Species 0.000 description 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 235000004877 Vaccaria hispanica subsp hispanica Nutrition 0.000 description 1
- 206010047998 Withdrawal bleed Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 241001079064 Zanthoxylum schinifolium Species 0.000 description 1
- 244000089698 Zanthoxylum simulans Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940046989 clomiphene citrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000001209 crocus sativus l. Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating infertility and a preparation method thereof, which takes clam shell, achyranthes root, beautiful sweetgum fruit, officinal magnolia bark, cowherb seed, patrinia scabiosaefolia link, akebia stem, garden balsam stem, snakegourd fruit, motherwort, epimedium herb, glossy privet fruit, turtle shell, saffron crocus, green pepper and probiotics as raw materials. The traditional Chinese medicine composition for treating infertility has a remarkable treatment effect on infertility.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating infertility and a preparation method thereof.
Background
In clinical medicine, the infertility of couples in the childbearing age group is called as infertility of the pregnant women after more than three years of marriage. There are many reasons for infertility, and the reasons can be divided into two main categories: organic causes and physical functional causes. The organic reasons generally can not achieve the treatment of infertility through the conditioning treatment of medicines, and modern medicine is realized by means of operations or artificial fertilization and the like. The infertility caused by physical function reasons has a plurality of reasons, and the treatment of some symptoms such as hysteromyoma, fallopian tube dredging, inflammation and the like by western medicines can not be well solved. At present, some traditional Chinese medicine prescriptions have certain curative effect, but the clinical effect is not ideal.
At present, hospitals for treating infertility and irregular menstruation are available in the market, the production of gynecological medicines keeps high-speed growth, the market is competitive, but the curative effect and the cure rate are difficult to guarantee, and the western medicine injection hormone needle therapy is frequently adopted in medicine, but the obtained curative effect is general, the body of a female is damaged, and the physiological health of the female is not facilitated. The traditional Chinese medicine has the history of over 2000 years for treating infertility in China, accumulates a large amount of clinical experience and theoretical basis, and has the unique advantages of dialectical treatment and strong pertinence. The effective components of the used Chinese herbal medicines are selectively utilized by different histiocytes after entering the organism and participate in the metabolism of the organism, and almost no toxic or side effect is generated.
Patent CN108042681A provides a Chinese medicinal composition for treating infertility and a preparation method thereof, the raw materials of the composition comprise wine-fried white peony root, red peony root, rhizoma corydalis, poria, cistanche deserticola, rhizoma ligustici wallichii, vinegar-processed rhizoma cyperi, prepared rhizome of rehmannia, angelica, salvia miltiorrhiza and the like, but the curative effect is poor, and the infertility symptom of polycystic ovary syndrome ovulation failure is not solved.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a traditional Chinese medicine composition for treating infertility and a preparation method thereof.
In order to solve the technical problems, the invention adopts the technical scheme that:
a preparation method of a traditional Chinese medicine composition for treating infertility comprises the following steps:
p1 mixing Concha Meretricis Seu Cyclinae, radix Achyranthis bidentatae, fructus Liquidambaris, cortex Magnoliae officinalis, semen Vaccariae, herba Patriniae, caulis Akebiae, herba speranskiae tuberculatae, fructus Trichosanthis, herba Leonuri, herba Epimedii, fructus Ligustri Lucidi, carapax Trionycis, and stigma croci, pulverizing, and sieving to obtain powder A;
p2 subjecting the powder A to steam explosion to obtain powder B;
p3 baking the medicinal powder B to obtain baked medicinal powder;
p4, mixing the baked powder and the synergist, feeding the mixture into an extraction tank, taking water as an extraction solvent, and filtering to obtain an extract liquid;
p5 ultrafiltering and concentrating the extract by using a polysulfone ultrafiltration membrane to obtain a concentrated solution;
p6 spray the concentrated solution to prepare powder, and obtain the traditional Chinese medicine composition for treating infertility after vacuum plastic package.
The Concha Meretricis Seu Cyclinae has effects of nourishing yin, promoting fluid production, softening and resolving hard mass; the achyranthes root has the effects of removing blood stasis, stimulating the menstrual flow, tonifying liver and kidney, strengthening bones and muscles, inducing diuresis, treating stranguria and drawing blood downward; the fructus liquidambaris has the effects of dispelling wind, activating collaterals and inducing diuresis; cortex Magnolia officinalis has effects in eliminating dampness, eliminating phlegm, descending qi, and relieving fullness; the snakegourd fruit has the effects of clearing heat and removing phlegm, and relieving chest stuffiness and dissipating stagnation; herba Leonuri has effects of promoting blood circulation, regulating menstruation, promoting diuresis, relieving swelling, clearing away heat and toxic materials, and can be used for treating menoxenia, dysmenorrhea, amenorrhea, lochiorrhea, edema, oliguria, and pyocutaneous disease; herba Epimedii has effects of invigorating kidney yang, strengthening tendons and bones, and dispelling pathogenic wind and dampness; fructus Ligustri Lucidi has effects in invigorating kidney yin, nourishing yin, and prolonging life; carapax Trionycis has effects in nourishing yin, suppressing yang hyperactivity, relieving fever, removing steam, softening and resolving hard mass; stigma croci Sativi has effects of promoting blood circulation for removing blood stasis, resolving stagnation and resolving hard mass, and can be used for treating female amenorrhea and puerperal abdominal pain due to blood stasis; the herbs harmonize yin and yang, reinforce each other, strengthen body resistance to eliminate pathogenic factors, and directly reach the focus.
The cowherb seed has the effects of promoting blood circulation, stimulating the menstrual flow, promoting lactation, reducing swelling, inducing diuresis and treating stranguria; herba Patriniae has effects of clearing away heat and toxic materials, removing blood stasis, and expelling pus; the akebia trifoliate has the effects of inducing diuresis for treating stranguria, clearing away heart-fire and relieving restlessness; the garden balsam stem has the effects of dispelling wind and eliminating dampness, relaxing muscles and tendons, promoting blood circulation, removing blood stasis, relieving swelling, removing toxic substances and relieving pain; the three components are jointly used in the specific traditional Chinese medicine formula group of the invention, so that the traditional Chinese medicine formula group can harmonize yin and yang, strengthen body resistance and eliminate pathogenic factors, enhance the efficacy, treat symptoms and consolidate the root.
The cell wall in the adopted medicine is further crushed by a steam explosion treatment mode before extraction, so that the pharmacodynamic ingredients in the medicine can be fully released, the subsequent extraction efficiency is improved, and the promotion of the pharmacodynamic effect is facilitated.
The invention adopts a two-stage heating baking mode to treat the medicinal materials, thereby avoiding the inactivation of the medicinal effect caused by overhigh temperature rise rate.
As a preferred scheme, the preparation method of the traditional Chinese medicine composition for treating the infertility comprises the following steps:
p1 mixing and crushing 2-4 parts by weight of clam shell, 5-7 parts by weight of radix achyranthis bidentatae, 1-3 parts by weight of fructus liquidambaris, 1-2 parts by weight of mangnolia officinalis, 4-6 parts by weight of cowherb seed, 3-5 parts by weight of patrinia scabiosaefolia, 2-4 parts by weight of caulis akebiae trifoliate, 7-9 parts by weight of garden balsam stem, 3-5 parts by weight of snakegourd fruit, 4-6 parts by weight of motherwort, 2-4 parts by weight of herba epimedii, 5-7 parts by weight of glossy privet fruit, 1-3 parts by weight of turtle shell and 1-3 parts by weight of saffron crocus, and sieving the mixture with a 10-30-mesh sieve to obtain medicinal powder A;
p2 performing steam explosion treatment on the powder A for 140 and 160s under the pressure of 4.8-5.4MPa to obtain powder B;
p3, performing second-order baking treatment on the medicinal powder B to obtain baked medicinal powder; in the second-order baking treatment, the whole process adopts carbon dioxide protective atmosphere and is stirred at the rotating speed of 20-35rpm, the temperature is firstly raised to 178-fold 182 ℃ and is preserved for 210-fold 230s, and then the temperature is raised to 255-fold 265 ℃ and is preserved for 380-fold 420 s;
p4, mixing the baked powder and the synergist in a mass ratio of (22-25):1, sending the mixture into an extraction tank, taking water as an extraction solvent, extracting at 174-177 ℃, under the extraction pressure of 2.1-2.4MPa for 28-35min, and filtering to obtain an extract liquid, wherein the ratio of the baked powder to the water bath is 1kg: 2.8-3.5L;
p5 ultrafiltering and concentrating the extract to 15-20% of the original volume by using a polysulfone ultrafiltration membrane to obtain a concentrated solution; the technological parameters of ultrafiltration concentration are that the cross flow speed is 3-5cm/s, the operation gauge pressure is 0.04-0.08MPa, and the temperature is 30-35 ℃;
p6 spray-drying the concentrated solution with centrifugal spray-dryer to obtain powder, vacuum packaging to obtain the Chinese medicinal composition for treating infertility; the technological parameters of the spray powder preparation are that the air inlet pressure is 0.4-0.5MPa, the atomization frequency is 50-65Hz, the striker interval is 5-8s, the air inlet temperature is 185-plus-one 195 ℃, and the feeding speed is 230-plus-one 250 mL/h.
The synergist is at least one of green pricklyash peel and probiotic freeze-dried powder.
The green pricklyash peel can treat spleen-kidney yang deficiency, waist cold and weak feet, tooth floating, and edema ascites of dysmenorrheal, knee pain, chronic nephritis and nephrotic syndrome, and can be combined with the probiotic freeze-dried powder prepared by the specific method of the invention to be used as a synergist of the traditional Chinese medicine composition for treating infertility, so that the synergist can eliminate pathogenic factors, strengthen body resistance, consolidate the constitution, and coordinate the functions of viscera and meridians, thereby correcting the excess and partial decline of yin and yang of the organism, restoring the balance of yin and yang, and further improving the curative effect of the traditional Chinese medicine composition.
As a preferable scheme, the synergist is a mixture of green pricklyash peel and probiotic freeze-dried powder in a mass ratio of (1-3) to (1-3).
As a more preferable scheme, the synergist is a mixture of green pricklyash peel and probiotic freeze-dried powder in a mass ratio of 1: 1.
The preparation method of the probiotic freeze-dried powder comprises the following steps:
d1, inoculating the mixed strains to a seed culture medium, and culturing to obtain a seed solution;
d2 inoculating the seed liquid into a fermentation tank, and performing electrifying treatment and anaerobic fermentation during fermentation to obtain fermentation liquid; in the electrifying treatment, direct current is adopted;
d3, carrying out centrifugal treatment on the fermentation liquor, and draining supernatant liquor to obtain bacterial sludge;
d4, placing the bacterial sludge in a freeze dryer, and performing freeze drying treatment to obtain the probiotic freeze-dried powder.
The probiotic freeze-dried powder prepared by the specific method of the invention is rich in nisin and various globulins, can be harmonized with yin and yang and synergized with active substances such as various plant polysaccharides, plant flavones and the like contained in the components, and enhances the curative effect on patients with polycystic ovarian syndrome ovulation failure infertility. The invention also adopts the modes of electrifying and adding manganese acetate to promote the mass growth and propagation of the mixed strains: the activity of growth enzymes and the like participating in various metabolic activities in the mixed strain is remarkably improved under the electric stimulation, which is beneficial to increasing the yield of nisin; the addition of a proper amount of manganese element can promote the yield of beneficial substances such as nisin and the like.
As a preferred scheme, the preparation method of the probiotic freeze-dried powder comprises the following steps:
d1 mixing the strains to 103-104Inoculating the inoculation amount of CFU/mL into a seed culture medium, and culturing at 37-40 ℃ for 25-35h to obtain a seed solution;
d2 inoculating the seed liquid into a fermentation tank, wherein the fermentation temperature is 37-40 ℃, and the fermentation period adopts electrification treatment and anaerobic fermentation for 140-160h to obtain fermentation liquid; the mass ratio of the seed liquid to the nutrient solution in the fermentation tank is (1-4) to 100; in the electrifying treatment, direct current with the current of 2.8-3.2mA is adopted, and the electrification is carried out once every 12-18s, wherein the duration of each time is 0.1-0.4 s;
d3, centrifuging the fermentation liquor by adopting a tubular centrifuge, and draining supernatant liquor to obtain bacterial sludge; the rotation speed of the centrifugal treatment is 11000-12000rpm, and the centrifugal time length is 2-4 min;
d4, placing the bacterial sludge in a freeze dryer, and performing freeze drying treatment to obtain the probiotic freeze-dried powder; the technological parameters of the freeze drying treatment are that the lowest temperature value is (-45) - (-40) DEG C, the freezing time is 8-10h, and the total drying time is 42-48 h.
The mixed strain is at least two of lactococcus lactis, Lactobacillus chaff-like bacteria and Lactobacillus Fuji.
Preferably, the mixed strain is a mixture of lactococcus lactis, Lactobacillus chaff-like bacteria and Lactobacillus Fuji in a mass ratio of (1-4) to (1-4).
The seed culture medium consists of the following raw materials: peptone, beef extract, yeast extract, glucose, dipotassium hydrogen phosphate, ammonium citrate, magnesium acetate and water.
As a preferable scheme, the seed culture medium is composed of the following raw materials in parts by weight: 10-13 parts of peptone, 8-10 parts of beef extract, 5-7 parts of yeast extract, 22-26 parts of glucose, 2-5 parts of dipotassium hydrogen phosphate, 2-5 parts of ammonium citrate, 0.3-0.7 part of magnesium acetate and 28-35 parts of water.
The nutrient solution in the fermentation tank consists of the following raw materials: peptone, beef extract, yeast extract, glucose, potassium dihydrogen phosphate, ammonium citrate, magnesium acetate, manganese acetate and water.
As a preferable scheme, the nutrient solution in the fermentation tank is composed of the following raw materials in parts by weight: 12-18 parts of peptone, 10-15 parts of beef extract, 8-12 parts of yeast extract, 22-28 parts of glucose, 4-6 parts of monopotassium phosphate, 4-6 parts of ammonium citrate, 0.6-1 part of magnesium acetate, 0.7-1.1 part of manganese acetate and 160 parts of water by weight.
The invention has the beneficial effects that:
1. the traditional Chinese medicine composition for treating infertility and the preparation method thereof are provided, the traditional Chinese medicine composition for effectively improving the serum sex hormone level (luteinizing hormone, testosterone and estradiol) is obtained by taking clam shells, achyranthes roots, beautiful sweetgum fruits, officinal magnolia bark, cowherb seeds, patrinia scabiosaefolia, akebia stems, garden balsam stems, snakegourd fruits, motherwort, epimedium herbs, glossy privet fruits, turtle shells, saffron crocus, green Chinese prickly ash and probiotics and the like as raw materials; obviously improves the thickness of the endometrium and the pregnancy rate, and has good treatment effect on patients with ovulation failure infertility caused by polycystic ovarian syndrome.
2. The preparation method of the probiotic freeze-dried powder is provided, the synergist of the traditional Chinese medicine composition for treating infertility is obtained by adopting electrification and manganese acetate as means for promoting the reproduction and development of mixed strains, and the drug effect is remarkably improved.
Detailed Description
The above summary of the present invention is described in further detail below with reference to specific embodiments, but it should not be understood that the scope of the above subject matter of the present invention is limited to the following examples.
Introduction of some raw materials in this application:
clam shell: mactra veneriformis Reeve, from Bozhou, Inc., Yihongtang pharmaceutical Co. The efficacy is as follows: nourish yin, promote the production of body fluid, soften hardness and dissipate nodulation.
Achyranthes root: achyranthes bidentata Bl is a dry root of Achyranthes bidentata belonging to Amaranthaceae, and is from Bozhou city Yihongtang pharmaceutical Co. The efficacy is as follows: dispel blood stasis and dredge channels, tonify liver and kidney, strengthen tendons and bones, induce diuresis and treat stranguria, and draw blood downward.
The road is through: liquidambar formosana Hance, a dry mature infructescence of a Liquidambar formosana tree of Hamamelidaceae, from Yihongtang pharmaceutical industry Co., Ltd, Bozhou city. The efficacy is as follows: dispel wind, activate collaterals, induce diuresis.
Magnolia officinalis: magnolia of finalis Rehd. et wils. var. bioloba Rehd. et wils. is dry bark, root bark and branch bark of Magnolia officinalis or Magnolia officinalis of Magnoliaceae, and is from the billion Hongtong pharmaceutical industry Co., Ltd. The efficacy is as follows: dry dampness and resolve phlegm, descend qi and remove fullness.
Seed of cowherb: vaccaria segetalis (Neck.) Garcke, a dry mature seed of Dianthus chinensis, belonging to Caryophyllaceae, comes from cooperative society of Chinese medicinal plant plantation in heat-treating city in Bozhou city. The efficacy is as follows: promoting blood circulation, dredging channels, promoting lactation, relieving swelling, inducing diuresis, and treating stranguria.
Herba patriniae: patrini scabiosaefolia from a mirror flower arrangement in the city of Bozhou, Hongshan, specialty Chinese medicinal plant cooperative. The efficacy is as follows: clear heat and remove toxicity, dispel stasis and expel pus.
Caulis akebiae trifoliate: akebia tri foliata (Thunb.) Koidz, from cooperative society of Chinese medicinal plant for treating heat in the city of Bozhou. The efficacy is as follows: induce diuresis to treat stranguria, clear heart fire and relieve restlessness.
Garden balsam stem: phoma leptostachya l.subsp.asitica (Hara) Kitamura, which is a whole plant of kombu leaves of euphorbiaceae, from medicinal material company, total medicinal material company, ohui, mn city. The efficacy is as follows: dispelling pathogenic wind and removing dampness, relieving rigidity of muscles and promoting blood circulation, removing blood stasis and detumescence, removing toxic substance and relieving pain.
And (3) snakegourd fruit: trichosanthes kirilowii maxim, from tianyang pharmaceutical ltd, bei yi county. The efficacy is as follows: clear heat and remove phlegm, relieve chest stuffiness and dissipate nodulation. The invention adopts the pericarp of snakegourd fruit.
Motherwort: leonurus japonica Houtt, from Bozhou, a hundred million Hongtong pharmaceutical Co., Ltd. The efficacy is as follows: promoting blood circulation to regulate menstruation, inducing diuresis to alleviate edema, and clearing away heat and toxic materials; can be used for treating menoxenia, dysmenorrhea, amenorrhea, lochiorrhea, edema, oliguria, pyocutaneous disease, and toxic swelling.
Herba epimedii: epimedium brevicornu Maxim, a dried leaf of Epimedium brevicornum Maxim, a berberidaceae plant, from Jie Congtang pharmaceutical Co., Ltd. The efficacy is as follows: tonify kidney yang, strengthen tendons and bones, dispel wind-damp.
Glossy privet fruit: fructus Ligustri Lucidi, a fruit of Ligustrum lucidum ait of Oleaceae, is from the Bozhou Renyuyi Chinese medicinal materials marketing Co., Ltd. The efficacy is as follows: tonify kidney yin, nourish yin and prolong life.
Turtle shell: trionyx sinensis Wiegmann, from the general Water agency, Hanshou county, Changde, Hunan. The efficacy is as follows: nourish yin and suppress yang, defervesce and remove steaming, soften hardness and dissipate nodulation.
Saffron: crocus sativus l. from bozhou renyi chinese medicinal material sales limited. The efficacy is as follows: promoting blood circulation, removing blood stasis, resolving stagnation, and treating amenorrhea and puerperal abdominal pain due to blood stasis.
Green pepper: zanthoxylum schinifolium sieb. et Zucc, from qiangyang agricultural development ltd, chongqing. The efficacy is as follows: treating spleen and kidney yang deficiency, waist cold and weak feet, teeth and teeth floating, dysmenorrhea, knee pain, chronic nephritis, and edema ascites of nephrotic syndrome.
Lactococcus lactis: lactococcus lactis provided by China general microbiological culture Collection center, CGMCC: 1.15072.
lactobacillus chaff-like bacteria: lactobacillus parafarraginis provided by China general microbiological culture Collection center (CGMCC): 1.15605.
lactococcus fuscata: lactococcus fujiensis provided by China general microbiological culture Collection center, CGMCC: 1.10453.
peptone, CAS: 73049-73-7, available from Onzhiji technologies, Inc.
Beef extract, CAS: 68990-09-0 from Hubei Shinshun Biotechnology, Inc.
Yeast extract is from Shandong Yubao Biotech GmbH.
Example 1
A preparation method of a traditional Chinese medicine composition for treating infertility comprises the following steps:
p1 mixing and crushing 3 parts by weight of clam shell, 6 parts by weight of radix achyranthis bidentatae, 2 parts by weight of fructus liquidambaris, 1 part by weight of cortex magnoliae officinalis, 5 parts by weight of cowherb seed, 4 parts by weight of patrinia scabiosaefolia, 3 parts by weight of akebia trifoliate, 8 parts by weight of garden balsam stem, 4 parts by weight of snakegourd fruit, 5 parts by weight of motherwort, 3 parts by weight of epimedium herb, 6 parts by weight of glossy privet fruit, 2 parts by weight of turtle shell and 1 part by weight of saffron crocus, and sieving by a 20-mesh sieve to obtain medicinal powder A;
p2 subjecting the powder A to steam explosion under 5MPa for 150s to obtain powder B;
p3, performing second-order baking treatment on the medicinal powder B to obtain baked medicinal powder; in the second-order baking treatment, the whole process is stirred at the rotating speed of 30rpm in the carbon dioxide protective atmosphere, the temperature is firstly increased to 180 ℃ and is kept for 220s, and then the temperature is increased to 260 ℃ and is kept for 400 s;
p4, mixing the baked powder and the synergist in a mass ratio of 23:1, sending the mixture into an extraction tank, taking water as an extraction solvent, extracting at 175 ℃, under an extraction pressure of 2.2MPa for 30min, wherein the ratio of the baked powder to water bath is 1kg:3L, filtering, and taking supernatant to obtain extract liquor;
p5 ultrafiltering and concentrating the extract to 18% of the original volume by using a polysulfone ultrafiltration membrane to obtain a concentrated solution; the technological parameters of ultrafiltration concentration are that the cross flow speed is 4cm/s, the operation gauge pressure is 0.06MPa, and the temperature is 30 ℃;
p6 spray-drying the concentrated solution with centrifugal spray-dryer to obtain powder, vacuum packaging to obtain the Chinese medicinal composition for treating infertility; the technological parameters of the spray powder preparation are that the air inlet pressure is 0.45MPa, the atomization frequency is 60Hz, the interval of firing pins is 6s, the air inlet temperature is 190 ℃, and the feeding speed is 240 mL/h.
The synergist is a mixture of green pricklyash peel and probiotic freeze-dried powder in a mass ratio of 1: 1.
The preparation method of the probiotic freeze-dried powder comprises the following steps:
d1 mixing the strains to 104Inoculating the inoculation amount of CFU/mL into a seed culture medium, and culturing at 40 ℃ for 30h to obtain a seed solution;
d2 inoculating the seed liquid into a fermentation tank, fermenting at 40 ℃, and performing electrification treatment and anaerobic fermentation for 150 hours during fermentation to obtain fermentation liquid; the mass ratio of the seed liquid to the nutrient solution in the fermentation tank is 3: 100; in the electrifying treatment, direct current with the current of 3mA is adopted, and the electrification is carried out once every 15s and lasts for 0.3s each time;
d3, centrifuging the fermentation liquor by adopting a tubular centrifuge, and draining supernatant liquor to obtain bacterial sludge; the rotation speed of the centrifugal treatment is 12000rpm, and the centrifugal time is 3 min;
d4, placing the bacterial sludge in a freeze dryer, and performing freeze drying treatment to obtain the probiotic freeze-dried powder; the technological parameters of the freeze drying treatment are that the lowest temperature is-42 ℃, the freezing time is 9h, and the total drying time is 45 h.
The mixed strain is a mixture of lactococcus lactis, lactobacillus chaff-like bacteria and lactobacillus Fuji in a mass ratio of 2:1: 1.
The seed culture medium is composed of the following raw materials in parts by weight: 12 parts by weight of peptone, 9 parts by weight of beef extract, 6 parts by weight of yeast extract, 25 parts by weight of glucose, 3 parts by weight of dipotassium hydrogen phosphate, 3 parts by weight of ammonium citrate, 0.5 part by weight of magnesium acetate and 30 parts by weight of water.
The nutrient solution in the fermentation tank is composed of the following raw materials in parts by weight: 15 parts of peptone, 12 parts of beef extract, 10 parts of yeast extract, 25 parts of glucose, 5 parts of monopotassium phosphate, 5 parts of ammonium citrate, 0.8 part of magnesium acetate, 0.9 part of manganese acetate and 150 parts of water.
Example 2
Essentially the same as example 1, except that: the synergist is green pricklyash peel.
Example 3
Essentially the same as example 1, except that: the synergist is probiotic freeze-dried powder.
The preparation method of the probiotic freeze-dried powder comprises the following steps:
d1 mixing the strains to 104Inoculating the inoculation amount of CFU/mL into a seed culture medium, and culturing at 40 ℃ for 30h to obtain a seed solution;
d2 inoculating the seed liquid into a fermentation tank, fermenting at 40 ℃, and performing electrification treatment and anaerobic fermentation for 150 hours during fermentation to obtain fermentation liquid; the mass ratio of the seed liquid to the nutrient solution in the fermentation tank is 3: 100; in the electrifying treatment, direct current with the current of 3mA is adopted, and the electrification is carried out once every 15s and lasts for 0.3s each time;
d3, centrifuging the fermentation liquor by adopting a tubular centrifuge, and draining supernatant liquor to obtain bacterial sludge; the rotation speed of the centrifugal treatment is 12000rpm, and the centrifugal time is 3 min;
d4, placing the bacterial sludge in a freeze dryer, and performing freeze drying treatment to obtain the probiotic freeze-dried powder; the technological parameters of the freeze drying treatment are that the lowest temperature is-42 ℃, the freezing time is 9h, and the total drying time is 45 h.
The mixed strain is a mixture of lactococcus lactis, lactobacillus chaff-like bacteria and lactobacillus Fuji in a mass ratio of 2:1: 1.
The seed culture medium is composed of the following raw materials in parts by weight: 12 parts by weight of peptone, 9 parts by weight of beef extract, 6 parts by weight of yeast extract, 25 parts by weight of glucose, 3 parts by weight of dipotassium hydrogen phosphate, 3 parts by weight of ammonium citrate, 0.5 part by weight of magnesium acetate and 30 parts by weight of water.
The nutrient solution in the fermentation tank is composed of the following raw materials in parts by weight: 15 parts of peptone, 12 parts of beef extract, 10 parts of yeast extract, 25 parts of glucose, 5 parts of monopotassium phosphate, 5 parts of ammonium citrate, 0.8 part of magnesium acetate, 0.9 part of manganese acetate and 150 parts of water.
Example 4
A preparation method of a traditional Chinese medicine composition for treating infertility comprises the following steps:
p1 mixing and crushing 3 parts by weight of clam shell, 6 parts by weight of radix achyranthis bidentatae, 2 parts by weight of fructus liquidambaris, 1 part by weight of cortex magnoliae officinalis, 5 parts by weight of cowherb seed, 4 parts by weight of patrinia scabiosaefolia, 3 parts by weight of akebia trifoliate, 8 parts by weight of garden balsam stem, 4 parts by weight of snakegourd fruit, 5 parts by weight of motherwort, 3 parts by weight of epimedium herb, 6 parts by weight of glossy privet fruit, 2 parts by weight of turtle shell and 1 part by weight of saffron crocus, and sieving by a 20-mesh sieve to obtain medicinal powder A;
p2 subjecting the powder A to steam explosion under 5MPa for 150s to obtain powder B;
p3, performing second-order baking treatment on the medicinal powder B to obtain baked medicinal powder; in the second-order baking treatment, the whole process is stirred at the rotating speed of 30rpm in the carbon dioxide protective atmosphere, the temperature is firstly increased to 180 ℃ and is kept for 220s, and then the temperature is increased to 260 ℃ and is kept for 400 s;
p4 feeding the baked medicinal powder into an extraction tank, taking water as an extraction solvent, extracting at 175 ℃ under 2.2MPa for 30min, wherein the ratio of the baked medicinal powder to water bath is 1kg:3L, and filtering to obtain an extract;
p5 ultrafiltering and concentrating the extract to 18% of the original volume by using a polysulfone ultrafiltration membrane to obtain a concentrated solution; the technological parameters of ultrafiltration concentration are that the cross flow speed is 4cm/s, the operation gauge pressure is 0.06MPa, and the temperature is 30 ℃;
p6 spray-drying the concentrated solution with centrifugal spray-dryer to obtain powder, vacuum packaging to obtain the Chinese medicinal composition for treating infertility; the technological parameters of the spray powder preparation are that the air inlet pressure is 0.45MPa, the atomization frequency is 60Hz, the interval of firing pins is 6s, the air inlet temperature is 190 ℃, and the feeding speed is 240 mL/h.
Example 5
Essentially the same as example 1, except that: p1 contains neither the cowherb nor the Patrinia scabiosaefolia FIq.
Example 6
Essentially the same as example 1, except that: p1 contains none of semen Vaccariae, herba Patriniae and caulis Akebiae.
Example 7
Essentially the same as example 3, except that:
the preparation method of the probiotic freeze-dried powder comprises the following steps:
d1 mixing the strains to 104Inoculating the inoculation amount of CFU/mL into a seed culture medium, and culturing at 40 ℃ for 30h to obtain a seed solution;
d2 inoculating the seed solution into a fermentation tank, and performing anaerobic fermentation at 40 ℃ for 150h to obtain a fermentation solution; the mass ratio of the seed liquid to the nutrient solution in the fermentation tank is 3: 100;
d3, centrifuging the fermentation liquor by adopting a tubular centrifuge, and draining supernatant liquor to obtain bacterial sludge; the rotation speed of the centrifugal treatment is 12000rpm, and the centrifugal time is 3 min;
d4, placing the bacterial sludge in a freeze dryer, and performing freeze drying treatment to obtain the probiotic freeze-dried powder; the technological parameters of the freeze drying treatment are that the lowest temperature is-42 ℃, the freezing time is 9h, and the total drying time is 45 h.
The mixed strain is a mixture of lactococcus lactis, lactobacillus chaff-like bacteria and lactobacillus Fuji in a mass ratio of 2:1: 1.
The seed culture medium is composed of the following raw materials in parts by weight: 12 parts by weight of peptone, 9 parts by weight of beef extract, 6 parts by weight of yeast extract, 25 parts by weight of glucose, 3 parts by weight of dipotassium hydrogen phosphate, 3 parts by weight of ammonium citrate, 0.5 part by weight of magnesium acetate and 30 parts by weight of water.
The nutrient solution in the fermentation tank is composed of the following raw materials in parts by weight: 15 parts of peptone, 12 parts of beef extract, 10 parts of yeast extract, 25 parts of glucose, 5 parts of monopotassium phosphate, 5 parts of ammonium citrate, 0.8 part of magnesium acetate, 0.9 part of manganese acetate and 150 parts of water.
Example 8
Essentially the same as example 3, except that:
the preparation method of the probiotic freeze-dried powder comprises the following steps:
d1 mixing the strains to 104Inoculating the inoculation amount of CFU/mL into a seed culture medium, and culturing at 40 ℃ for 30h to obtain a seed solution;
d2 inoculating the seed liquid into a fermentation tank, fermenting at 40 ℃, and performing electrification treatment and anaerobic fermentation for 150 hours during fermentation to obtain fermentation liquid; the mass ratio of the seed liquid to the nutrient solution in the fermentation tank is 3: 100; in the electrifying treatment, direct current with the current of 3mA is adopted, and the electrification is carried out once every 15s and lasts for 0.3s each time;
d3, centrifuging the fermentation liquor by adopting a tubular centrifuge, and draining supernatant liquor to obtain bacterial sludge; the rotation speed of the centrifugal treatment is 12000rpm, and the centrifugal time is 3 min;
d4, placing the bacterial sludge in a freeze dryer, and performing freeze drying treatment to obtain the probiotic freeze-dried powder; the technological parameters of the freeze drying treatment are that the lowest temperature is-42 ℃, the freezing time is 9h, and the total drying time is 45 h.
The mixed strain is a mixture of lactococcus lactis, lactobacillus chaff-like bacteria and lactobacillus Fuji in a mass ratio of 2:1: 1.
The seed culture medium is composed of the following raw materials in parts by weight: 12 parts by weight of peptone, 9 parts by weight of beef extract, 6 parts by weight of yeast extract, 25 parts by weight of glucose, 3 parts by weight of dipotassium hydrogen phosphate, 3 parts by weight of ammonium citrate, 0.5 part by weight of magnesium acetate and 30 parts by weight of water.
The nutrient solution in the fermentation tank is composed of the following raw materials in parts by weight: 15 parts of peptone, 12 parts of beef extract, 10 parts of yeast extract, 25 parts of glucose, 5 parts of monopotassium phosphate, 5 parts of ammonium citrate, 0.8 part of magnesium acetate and 150 parts of water.
Example 9
Essentially the same as example 1, except that:
in the step P3, performing common baking treatment on the medicinal powder B to obtain baked medicinal powder; in the ordinary baking treatment, the temperature is raised to 260 ℃ and kept for 400s, and the whole process is stirred at the rotating speed of 30rpm under the protective atmosphere of carbon dioxide.
Example 10
A preparation method of a traditional Chinese medicine composition for treating infertility comprises the following steps:
p1 mixing and crushing 3 parts by weight of clam shell, 6 parts by weight of radix achyranthis bidentatae, 2 parts by weight of fructus liquidambaris, 1 part by weight of cortex magnoliae officinalis, 5 parts by weight of cowherb seed, 4 parts by weight of patrinia scabiosaefolia, 3 parts by weight of akebia trifoliate, 8 parts by weight of garden balsam stem, 4 parts by weight of snakegourd fruit, 5 parts by weight of motherwort, 3 parts by weight of epimedium herb, 6 parts by weight of glossy privet fruit, 2 parts by weight of turtle shell and 1 part by weight of saffron crocus, and sieving by a 20-mesh sieve to obtain;
p2, performing second-order baking treatment on the medicinal powder A to obtain baked medicinal powder; in the second-order baking treatment, the whole process is stirred at the rotating speed of 30rpm in the carbon dioxide protective atmosphere, the temperature is firstly increased to 180 ℃ and is kept for 220s, and then the temperature is increased to 260 ℃ and is kept for 400 s;
p3, mixing the baked powder and the synergist in a mass ratio of 23:1, sending the mixture into an extraction tank, taking water as an extraction solvent, extracting at 175 ℃, under 2.2MPa for 30min, wherein the ratio of the baked powder to water bath is 1kg:3L, and filtering to obtain an extract;
p4 ultrafiltering and concentrating the extract to 18% of the original volume by using a polysulfone ultrafiltration membrane to obtain a concentrated solution; the technological parameters of ultrafiltration concentration are that the cross flow speed is 4cm/s, the operation gauge pressure is 0.06MPa, and the temperature is 30 ℃;
p5 spray-drying the concentrated solution with centrifugal spray-dryer to obtain powder, vacuum packaging to obtain the Chinese medicinal composition for treating infertility; the technological parameters of the spray powder preparation are that the air inlet pressure is 0.45MPa, the atomization frequency is 60Hz, the interval of firing pins is 6s, the air inlet temperature is 190 ℃, and the feeding speed is 240 mL/h.
The synergist is a mixture of green pricklyash peel and probiotic freeze-dried powder in a mass ratio of 1: 1.
The preparation method of the probiotic freeze-dried powder comprises the following steps:
d1 mixing the strains to 104Inoculating the inoculation amount of CFU/mL into a seed culture medium, and culturing at 40 ℃ for 30h to obtain a seed solution;
d2 inoculating the seed liquid into a fermentation tank, fermenting at 40 ℃, and performing electrification treatment and anaerobic fermentation for 150 hours during fermentation to obtain fermentation liquid; the mass ratio of the seed liquid to the nutrient solution in the fermentation tank is 3: 100; in the electrifying treatment, direct current with the current of 3mA is adopted, and the electrification is carried out once every 15s and lasts for 0.3s each time;
d3, centrifuging the fermentation liquor by adopting a tubular centrifuge, and draining supernatant liquor to obtain bacterial sludge; the rotation speed of the centrifugal treatment is 12000rpm, and the centrifugal time is 3 min;
d4, placing the bacterial sludge in a freeze dryer, and performing freeze drying treatment to obtain the probiotic freeze-dried powder; the technological parameters of the freeze drying treatment are that the lowest temperature is-42 ℃, the freezing time is 9h, and the total drying time is 45 h.
The mixed strain is a mixture of lactococcus lactis, lactobacillus chaff-like bacteria and lactobacillus Fuji in a mass ratio of 2:1: 1.
The seed culture medium is composed of the following raw materials in parts by weight: 12 parts by weight of peptone, 9 parts by weight of beef extract, 6 parts by weight of yeast extract, 25 parts by weight of glucose, 3 parts by weight of dipotassium hydrogen phosphate, 3 parts by weight of ammonium citrate, 0.5 part by weight of magnesium acetate and 30 parts by weight of water.
The nutrient solution in the fermentation tank is composed of the following raw materials in parts by weight: 15 parts of peptone, 12 parts of beef extract, 10 parts of yeast extract, 25 parts of glucose, 5 parts of monopotassium phosphate, 5 parts of ammonium citrate, 0.8 part of magnesium acetate, 0.9 part of manganese acetate and 150 parts of water.
Test example 1
Testing the pregnancy rate of the hamster: for each test group, 50 male mice and 50 female mice of Zhonghua hamster (five weeks old, provided by the university of Chongqing medical laboratory animal center) were used, and the male mice and the female mice of each test group were fed with the Chinese medicinal composition, respectively, and a control group fed with physiological saline alone was provided. Each group was given 20mg/kg of the composition intraperitoneally once a week for a total of five times. After the injection of cyclophosphamide in the fourth week, the gerbils are grouped and labeled according to the weight of the gerbils, and the dosage is calculated according to the weight before each administration and is administered once a day until the end of the experiment. At 6-8 weeks, the rats of the model and the normal rats were in the same cage, and thereafter only the Chinese medicinal composition was administered, and the physiological changes (mental, activity, secretion, etc.) during estrus of the rats were observed and whether the rats were pregnant or not was observed. At the end of the tenth week, mice were sacrificed by dislocation and pregnant mice were dissected and counted. And (3) pregnancy judgment: the red beaded particles can be seen in the oviduct of the female mouse; newborn mice: it was born ten weeks ago. Detection indexes are as follows: the pregnancy rate (%) of the Chinese hamster is the number of pregnant mice/the number of female mice in the group; compared with the traditional Chinese medicine composition only, the traditional Chinese medicine composition has statistical significance.
The test results are shown in table 1.
TABLE 1 pregnancy rates in female mice
Test example 2
Human clinical test:
200 patients with ovulation disorder infertility caused by polycystic ovarian syndrome are divided into 50 cases of treatment groups (1-3) and control groups by using a random number table method. The age distribution of the treatment group and the control group is 25-40 years, and the average (29.17 +/-6.45) years; the disease courses are respectively 3-10 years, and the average (6.46 +/-2.02) years; the infertility time is 1-5 years respectively, and the average (3.87 +/-1.76) years. The comparison of the general conditions of age, disease course, duration of infertility, etc. of the patients in each group did not show statistical differences (P > 0.05), indicating that the two groups are comparable.
Diagnostic criteria:
(1) western diagnostic criteria: according to the diagnosis standard of polycystic ovarian syndrome established by 2003 world conference of rotterdan: firstly, dilute ovulation or no ovulation; abnormal clinical manifestation and/or biochemical indexes of hyperandrogenism; ③ the ovarian polycystic variant, which accords with at least 2 of the above 3 items and eliminates related diseases such as cushing's syndrome, androgen-secreting tumor, and the like.
(2) The traditional Chinese medicine diagnosis standard is as follows: meets the diagnosis standard of the kidney yin deficiency infertility in the traditional Chinese medicine gynecology: the main symptoms are: prolonged infertility, premature menstruation, scanty menstruation or amenorrhea, and bright red menstruation; or even collapse or leak with prolonged menstruation time. Second symptoms are emaciation, dizziness, tinnitus, soreness and weakness of waist and knees, dysphoria with smothery sensation in chest, insomnia, dreaminess, dim eyesight, palpitation, loss of moisture in skin and dryness in yin. A slightly red and dry tongue with little coating and a thready or thready and rapid pulse. The diagnosis can be made by referring to tongue pulse conditions with the above main symptoms and 1-2 secondary symptoms.
(3) Inclusion criteria were: meeting the Chinese and Western diagnosis standard; ② 20-40 years old; third, voluntarily receive the treatment of the subject and sign the informed consent.
(4) Exclusion criteria: firstly, infertility (such as physiological defect, deformity and genetic factor) is caused by congenital factors; ② infertility caused by male factors; ③ diseases of the gravity, liver, kidney, hematopoietic system, etc. are combined; fourthly, the used medicines have allergic history; use of hormone-like drugs within 3 months.
The treatment method comprises the following steps:
control group: the clomiphene citrate tablet is taken orally at 50mg from 5 days of menstrual cycle or progesterone withdrawal bleeding, 1 time per day for 5 consecutive days, and is increased by 50mg/d per cycle if no ovulation occurs, but the maximum dose is not more than 150mg per day.
Treatment groups: the Chinese medicinal composition obtained in examples 1-3 of the present invention (treatment groups 1-3) was added to the control group, and the patients were asked to make a re-visit once a week to show the specific symptoms and to add or subtract the amount of the medicament. The preparation is decocted with water twice for a total of 400ml, and is taken orally in the morning and evening. Stopping treatment during menstrual period.
The four groups of patients are treated continuously for 3 months, and the curative effect is observed after the period, or until the pregnancy is confirmed, and the follow-up visit is 3 months.
And (3) observation of curative effect:
observation indexes are as follows: the clinical curative effects of two groups of patients are shown; ② two groups of patients serum sex hormone level changes: collecting 5ml of morning fasting blood from patients before treatment and on day 5 of 1 month period, and detecting Luteinizing Hormone (LH), testosterone (T) and estradiol (E2) levels; comparing the thickness of the endometrium of two groups of patients: the two groups adopt B ultrasonic dynamic monitoring on the thickness of the endometrium and the development of the follicles from the 10 th day of the menstrual cycle, and compare the thickness of the endometrium when the maximum diameter of the follicles in the two groups is more than 18 mm; clinical pregnancy rates were compared between the two groups: pregnancy rate (number of pregnancies/number of cases) × 100%; two groups were scored for the occurrence of ovarian hyperstimulation syndrome (OHSS).
Therapeutic efficacy judgment criteria clinical efficacy judgment criteria refer to the previous clinical study and are combined with clinical practice as follows: firstly, curing: the serum sex hormone of the patient is improved to a normal level, the menstruation rule is to be affected, and the pregnancy is to be performed; secondly, effect is displayed: the serum sex hormones and the menstrual cycle are basically restored to normal, and ovulation occurs, but pregnancy does not occur; ③ effective: the menstruation, color and quality of the menstruation are better, but the serum sex hormone is not obviously improved; fourthly, invalidation: neither serum sex hormone levels nor (or) menstruation improved or even aggravated, no ovulation. Effective rate (cure + significant effect + effective)/total number of cases.
The statistical method comprises the following steps: the database was built using SPSS17.0 software and statistical analysis was performed. The comparison between the counting data adopts X2 test, the comparison between the metering data adopts t test, and P is less than 0.05 to indicate that the difference has statistical significance.
And (3) testing results:
the clinical effects of two groups of patients are as follows: 25 cases are cured in a treatment group, 10 cases are obviously effective, 12 cases are effective, and the total effective rate is 94%; the control group heals 5 cases, has obvious effect of 11 cases and 7 cases, and has total effective rate of 46 percent. The total effective rate of the treatment group is higher than that of the control group, and the difference has statistical significance (P is less than 0.05).
② two groups of patients serum sex hormone level changes: the hormone levels before and after two groups of treatment are compared with the hormone levels before two groups of treatment, the hormone levels before two groups of treatment are compared without statistical difference (P is more than 0.05), and the hormone levels before two groups of treatment are comparable. The hormone levels in the two groups after treatment are improved compared with those before treatment (P is less than 0.05); wherein, the improvement range of the treatment group is larger than that of the control group, and the difference has statistical significance (P is less than 0.05), which is shown in table 2.
TABLE 2 serum sex hormone level changes in two groups of patients
Comparing the thickness and ovulation condition of the endometrium of two groups of patients: the ovulation promotion curative effect indexes of the two groups are obviously superior to those of a control group (P is less than 0.05) in comparison of the ovulation promotion curative effect indexes of mature follicles and the ovulation improvement conditions of the endometrium of the treatment group; the clinical pregnancy rate of the treatment group is 36.7 percent, which is higher than 16.7 percent of the control group, and the difference has statistical significance (P is less than 0.05). During the treatment process, no moderate or severe ovarian hyperstimulation syndrome occurs in the two groups. Specifically, the results are shown in Table 3.
TABLE 3 comparison of the two ovulation-promoting efficacy indexes
The Concha Meretricis Seu Cyclinae has effects of nourishing yin, promoting fluid production, softening and resolving hard mass; the achyranthes root has the effects of removing blood stasis, stimulating the menstrual flow, tonifying liver and kidney, strengthening bones and muscles, inducing diuresis, treating stranguria and drawing blood downward; the fructus liquidambaris has the effects of dispelling wind, activating collaterals and inducing diuresis; cortex Magnolia officinalis has effects in eliminating dampness, eliminating phlegm, descending qi, and relieving fullness; the cowherb seed has the effects of promoting blood circulation, stimulating the menstrual flow, promoting lactation, reducing swelling, inducing diuresis and treating stranguria; herba Patriniae has effects of clearing away heat and toxic materials, removing blood stasis, and expelling pus; the akebia trifoliate has the effects of inducing diuresis for treating stranguria, clearing away heart-fire and relieving restlessness; the garden balsam stem has the effects of dispelling wind and eliminating dampness, relaxing muscles and tendons, promoting blood circulation, removing blood stasis, relieving swelling, removing toxic substances and relieving pain; the snakegourd fruit has the effects of clearing heat and removing phlegm, and relieving chest stuffiness and dissipating stagnation; herba Leonuri has effects of promoting blood circulation, regulating menstruation, promoting diuresis, relieving swelling, clearing away heat and toxic materials, and can be used for treating menoxenia, dysmenorrhea, amenorrhea, lochiorrhea, edema, oliguria, and pyocutaneous disease; herba Epimedii has effects of invigorating kidney yang, strengthening tendons and bones, and dispelling pathogenic wind and dampness; fructus Ligustri Lucidi has effects in invigorating kidney yin, nourishing yin, and prolonging life; carapax Trionycis has effects in nourishing yin, suppressing yang hyperactivity, relieving fever, removing steam, softening and resolving hard mass; stigma croci Sativi has effects of promoting blood circulation for removing blood stasis, resolving stagnation and resolving hard mass, and can be used for treating female amenorrhea and puerperal abdominal pain due to blood stasis; the herbs harmonize yin and yang, reinforce each other, strengthen body resistance to eliminate pathogenic factors, and directly reach the focus.
The green pricklyash peel can treat spleen-kidney yang deficiency, waist cold and weak feet, tooth floating, and edema ascites of dysmenorrheal, knee pain, chronic nephritis and nephrotic syndrome, and can be combined with the probiotic freeze-dried powder prepared by the specific method of the invention to be used as a synergist of the traditional Chinese medicine composition for treating infertility, so that the synergist can eliminate pathogenic factors, strengthen body resistance, consolidate the constitution, and coordinate the functions of viscera and meridians, thereby correcting the excess and partial decline of yin and yang of the organism, restoring the balance of yin and yang, and further improving the curative effect of the traditional Chinese medicine composition.
The probiotic freeze-dried powder prepared by the specific method of the invention is rich in nisin and various globulins, can be harmonized with yin and yang and synergized with active substances such as various plant polysaccharides, plant flavones and the like contained in the components, and enhances the curative effect on patients with polycystic ovarian syndrome ovulation failure infertility. The invention also adopts the modes of electrifying and adding manganese acetate to promote the mass growth and propagation of the mixed strains: the activity of growth enzymes and the like participating in various metabolic activities in the mixed strain is remarkably improved under the electric stimulation, which is beneficial to increasing the yield of nisin; the addition of a proper amount of manganese element can promote the yield of beneficial substances such as nisin and the like.
Claims (8)
1. A preparation method of a traditional Chinese medicine composition for treating infertility is characterized by comprising the following steps:
p1 mixing Concha Meretricis Seu Cyclinae, radix Achyranthis bidentatae, fructus Liquidambaris, cortex Magnoliae officinalis, semen Vaccariae, herba Patriniae, caulis Akebiae, herba speranskiae tuberculatae, fructus Trichosanthis, herba Leonuri, herba Epimedii, fructus Ligustri Lucidi, carapax Trionycis, and stigma croci, pulverizing, and sieving to obtain powder A;
p2 subjecting the powder A to steam explosion to obtain powder B;
p3 baking the medicinal powder B to obtain baked medicinal powder;
p4, mixing the baked powder and the synergist, feeding the mixture into an extraction tank, taking water as an extraction solvent, and filtering to obtain an extract liquid;
p5 ultrafiltering and concentrating the extract by using a polysulfone ultrafiltration membrane to obtain a concentrated solution;
p6 spray the concentrated solution to prepare powder, and obtain the traditional Chinese medicine composition for treating infertility after vacuum plastic package.
2. The method of claim 1, wherein the step P1 comprises: mixing and crushing 2-4 parts of clam shell, 5-7 parts of achyranthes root, 1-3 parts of beautiful sweetgum fruit, 1-2 parts of officinal magnolia bark, 4-6 parts of cowherb seed, 3-5 parts of patrinia scabiosaefolia, 2-4 parts of akebia trifoliate, 7-9 parts of garden balsam stem, 3-5 parts of snakegourd fruit, 4-6 parts of motherwort, 2-4 parts of epimedium herb, 5-7 parts of glossy privet fruit, 1-3 parts of turtle shell and 1-3 parts of saffron crocus, and sieving the mixture by a 10-30-mesh sieve to obtain medicinal powder A.
3. The method of claim 1, wherein the method comprises the following steps: the synergist is at least one of green pricklyash peel and probiotic freeze-dried powder.
4. The method for preparing the traditional Chinese medicine composition for treating infertility according to claim 3, wherein the method for preparing the probiotic freeze-dried powder comprises the following steps:
d1, inoculating the mixed strains to a seed culture medium, and culturing to obtain a seed solution;
d2 inoculating the seed liquid into a fermentation tank, and performing electrifying treatment and anaerobic fermentation during fermentation to obtain fermentation liquid; in the electrifying treatment, direct current is adopted;
d3, carrying out centrifugal treatment on the fermentation liquor, and draining supernatant liquor to obtain bacterial sludge;
d4, placing the bacterial sludge in a freeze dryer, and performing freeze drying treatment to obtain the probiotic freeze-dried powder.
5. The method of claim 4 for preparing a Chinese medicinal composition for treating infertility, wherein the Chinese medicinal composition comprises: the mixed strain is at least two of lactococcus lactis, Lactobacillus chaff-like bacteria and Lactobacillus Fuji.
6. The method of claim 4 for preparing a Chinese medicinal composition for treating infertility, wherein the Chinese medicinal composition comprises: the seed culture medium consists of the following raw materials: peptone, beef extract, yeast extract, glucose, dipotassium hydrogen phosphate, ammonium citrate, magnesium acetate and water.
7. The method of claim 4 for preparing a Chinese medicinal composition for treating infertility, wherein the Chinese medicinal composition comprises: the nutrient solution in the fermentation tank consists of the following raw materials: peptone, beef extract, yeast extract, glucose, potassium dihydrogen phosphate, ammonium citrate, magnesium acetate, manganese acetate and water.
8. A traditional Chinese medicine composition for treating infertility is characterized in that: is prepared by the preparation method of the traditional Chinese medicine composition for treating the infertility according to any one of the claims 1 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110734255.0A CN113262259A (en) | 2021-06-30 | 2021-06-30 | Chinese medicinal composition for treating infertility and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110734255.0A CN113262259A (en) | 2021-06-30 | 2021-06-30 | Chinese medicinal composition for treating infertility and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113262259A true CN113262259A (en) | 2021-08-17 |
Family
ID=77236163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110734255.0A Pending CN113262259A (en) | 2021-06-30 | 2021-06-30 | Chinese medicinal composition for treating infertility and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113262259A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114532434A (en) * | 2022-03-10 | 2022-05-27 | 安徽神农泽中医药科技发展有限公司 | Preparation method and application of functional dendrobe coffee for dredging human gonad channel |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1565516A (en) * | 2003-06-09 | 2005-01-19 | 沈观印 | Medicine for treating woman sterility |
-
2021
- 2021-06-30 CN CN202110734255.0A patent/CN113262259A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1565516A (en) * | 2003-06-09 | 2005-01-19 | 沈观印 | Medicine for treating woman sterility |
Non-Patent Citations (2)
| Title |
|---|
| 于小霞等: "不孕症辨证论治刍议", 《陕西中医》 * |
| 王会敏: "中药补肾为主合氯菧酚治疗排卵障碍性不孕63例", 《河北中医》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114532434A (en) * | 2022-03-10 | 2022-05-27 | 安徽神农泽中医药科技发展有限公司 | Preparation method and application of functional dendrobe coffee for dredging human gonad channel |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108450656A (en) | A kind of method that Chinese herb residues orientation fermentation prepares functional feedstuff additive | |
| CN107349385A (en) | One group is used for fermented tcm composition that live pig nonreactive cultivates and preparation method thereof | |
| CN102488848A (en) | Traditional Chinese medicine composition used for treating high-pathogenicity porcine reproductive and respiratory syndrome, preparation method thereof, and application thereof | |
| CN103550625A (en) | Fermented traditional Chinese medicine for treating reduction of egg production of laying hens and preparation method thereof | |
| KR20160119999A (en) | Gongjindan based on dongibogam and method of manufacturing the same | |
| CN113262259A (en) | Chinese medicinal composition for treating infertility and preparation method thereof | |
| CN115969909B (en) | Traditional Chinese medicine composition and fermented traditional Chinese medicine preparation for improving sub-health of sow as well as preparation method and application of traditional Chinese medicine composition and fermented traditional Chinese medicine preparation | |
| CN105918658A (en) | Sheep feed for treating diarrhoea | |
| CN105663926A (en) | Uric acid-reducing plant enzyme and preparation method thereof | |
| CN102657798B (en) | Compound propolis composition to increase lactation yield of livestock and preparation method thereof | |
| CN104984296A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparation method thereof | |
| CN115300585A (en) | Weilong bone-strengthening wine for treating rheumatism bone disease and preparation method thereof | |
| CN111388639B (en) | Phenylethanoid glycoside and isoflavone extract for relieving menopausal syndrome and application thereof | |
| CN113398091A (en) | Capsule preparation for treating infertility and preparation method thereof | |
| CN113826882A (en) | Dietary nutrition supplement for preventing and treating diabetes and preparation process thereof | |
| CN106377700A (en) | Folium mori and bitter gourd tea and making method thereof | |
| CN112546164A (en) | Medicinal preparation for treating damp-heat in liver and gallbladder and preparation method thereof | |
| CN101934046B (en) | Semifluid extract of deer foetus and preparation method thereof | |
| CN116920039B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN104547859A (en) | Application of traditional Chinese medicine preparation in preparation of medicine for treating chronic tracheitis | |
| CN117085086B (en) | Qi and blood tonifying ferment and preparation process and application thereof | |
| CN105920539A (en) | Medicament for treating foot-and-mouth disease of sheep | |
| CN103768251B (en) | A kind of medicine killed virus in blood cell, improve human antibody's immunizing power | |
| CN117717599A (en) | Traditional Chinese medicine composition for relieving physical fatigue and preparation method and application thereof | |
| CN111956724A (en) | Traditional Chinese medicine preparation for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210817 |
|
| WD01 | Invention patent application deemed withdrawn after publication |